NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.53) by $0.12. The medical instruments supplier had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.54 million. View TransEnterix's earnings history.

1 brokers have issued 12 month price objectives for TransEnterix's shares. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 209.5% from the stock's current price. View analysts' price targets for TransEnterix.

Press coverage about TRXC stock has been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TransEnterix earned a news impact score of -2.4 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news about TransEnterix.

TransEnterix saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,980,000 shares, an increase of 130.6% from the June 15th total of 2,160,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 11.4% of the shares of the stock are sold short. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY) and Commerzbank (CZMWY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $0.32.

TransEnterix has a market capitalization of $16.75 million.

The official website for TransEnterix is www.transenterix.com.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.